Aurinia Pharmaceuticals Inc(AUPH)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AUPH Aurinia Pharmaceuticals Inc

交易中 07-23 15:20:35 EDT

15.30

-0.03

-0.23%

最高15.37	最低15.01	成交量35.36万
今开15.11	昨收15.33	日振幅2.35%
总市值19.67亿	流通市值18.19亿	总股本1.29亿
成交额538.83万	换手率0.30%	流通股本1.19亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AUPH","market":"US","secType":"STK","nameCN":"Aurinia Pharmaceuticals Inc","latestPrice":15.295,"timestamp":1784834429357,"preClose":15.33,"halted":0,"volume":353569,"delay":0,"changeRate":-0.0022831050228310596,"floatShares":118915567,"shares":128601671,"eps":2.174691,"marketStatus":"交易中","change":-0.035,"latestTime":"07-23 15:20:35 EDT","open":15.11,"high":15.37,"low":15.01,"amount":5388295.389231999,"amplitude":0.023483,"askPrice":15.3,"askSize":809,"bidPrice":15.28,"bidSize":225,"shortable":3,"etf":0,"ttmEps":2.174691,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1784836800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":951454800000,"exchange":"NASDAQ","adjPreClose":15.33,"preHourTrading":{"tag":"盘前","latestPrice":15.11,"preClose":15.33,"latestTime":"09:29 EDT","volume":627,"amount":9499.318983000001,"timestamp":1784813399999,"change":-0.22,"changeRate":-0.014351,"amplitude":0.027397},"postHourTrading":{"tag":"盘后","latestPrice":15.25,"preClose":15.33,"latestTime":"19:34 EDT","volume":47935,"amount":734926.526,"timestamp":1784763250648,"change":-0.08,"changeRate":-0.005219,"amplitude":0.00848},"volumeRatio":0.441524,"impliedVol":0.4995,"impliedVolPercentile":0.6295},"requestUrl":"/m/hq/s/AUPH","defaultTab":"news","newsList":[{"id":"1162218198","title":"Lupkynis显著降低肾脏相关事件或死亡风险达53%","url":"https://stock-news.laohu8.com/highlight/detail?id=1162218198","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162218198?lang=zh_cn&edition=full","pubTime":"2026-06-04 19:02","pubTimestamp":1780570951,"startTime":"0","endTime":"0","summary":"研究数据显示，药物Lupkynis与肾脏相关事件或死亡风险出现统计学上显著降低53%相关。这一发现突显了该疗法在改善患者临床结局方面的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141334772","title":"Aurinia Pharmaceuticals公布2026年第一季度财报及近期业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1141334772","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141334772?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:01","pubTimestamp":1778155297,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals Inc（以下简称“Aurinia”）近日披露了截至2026年3月31日的第一季度财务业绩，并同步更新了公司近期的业务动态。\n财报数据显示，本季度Aurinia在核心产品市场推广及研发管线推进方面取得显著进展。公司管理层表示，当前财务表现符合预期，各项运营指标保持稳健态势。\n与此同时，Aurinia还重点介绍了其在自身免疫疾病领域的最新研究突破。通过持续优化临床治疗方案，公司正加速拓展全球市场布局，为长期增长注入新动能。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176462033","title":"Aurinia制药公司或有价值权利包含Zetomipzomib、Everest、Enodia项目付款及超5000万美元净现金","url":"https://stock-news.laohu8.com/highlight/detail?id=1176462033","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176462033?lang=zh_cn&edition=full","pubTime":"2026-03-30 20:04","pubTimestamp":1774872252,"startTime":"0","endTime":"0","summary":"根据协议条款，Aurinia Pharmaceuticals Inc（AUPH）的或有价值权利（CVR）涵盖多项潜在收益来源。具体包括源自Zetomipzomib项目里程碑的付款、与Everest Therapeutics合作产生的收益、Enodia Pharmaceuticals相关项目的分成，以及公司账上超过5000万美元的净现金储备。\n这些CVR条款为投资者提供了额外的价值保障，将未来特定业务的成功与股东回报直接挂钩。分析师指出，净现金超过5000万美元这一条件尤为关键，它为公司在没有额外融资压力下推进核心研发提供了财务灵活性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH","KZR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109862455","title":"Aurinia Pharmaceuticals将以每股6.955美元现金加或有价值权利收购Kezar Life Sciences","url":"https://stock-news.laohu8.com/highlight/detail?id=1109862455","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109862455?lang=zh_cn&edition=full","pubTime":"2026-03-30 20:02","pubTimestamp":1774872146,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals Inc（Aurinia Pharmaceuticals）宣布，将以每股6.955美元现金加一项或有价值权利（CVR）的条件，收购Kezar Life Sciences Inc.（Kezar Life Sciences Inc.）。该交易旨在通过整合双方资源，增强在生物医药领域的研发实力与市场竞争力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH","KZR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111349840","title":"异动解读 | Aurinia Pharmaceuticals盘前大涨5.20%，因公布财报及新临床研究计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1111349840","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111349840?lang=zh_cn&edition=full","pubTime":"2026-02-26 19:47","pubTimestamp":1772106450,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals Inc今日盘前股价大涨5.20%，引起了市场的广泛关注。消息面上，公司公布了截至2025年12月31日的第四季度及全年财务业绩，并同步更新了近期的重要业务进展。同时，公司披露了研发战略新动向，计划于2026年上半年启动针对新适应症自身免疫疾病的临床研究，这标志着其在核心治疗领域的进一步拓展。这些积极的财务表现和研发进展增强了投资者对公司未来增长潜力的信心，从而推动了股价的显著上涨。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159840483","title":"Aurinia Pharmaceuticals Inc计划于2026年上半年启动针对新适应症自身免疫疾病的临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1159840483","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159840483?lang=zh_cn&edition=full","pubTime":"2026-02-26 19:06","pubTimestamp":1772104018,"startTime":"0","endTime":"0","summary":"生物制药公司Aurinia Pharmaceuticals Inc近日披露其研发战略新动向，预计将于2026年上半年开展针对除现有适应症外另一项自身免疫疾病的临床研究。该计划标志着公司在其核心治疗领域——自身免疫疾病方向的进一步拓展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178677601","title":"Aurinia Pharmaceuticals公布截至2025年12月31日的第四季度及全年财务业绩，并更新近期业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1178677601","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178677601?lang=zh_cn&edition=full","pubTime":"2026-02-26 19:04","pubTimestamp":1772103874,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals Inc公布了其截至2025年12月31日的第四季度及全年财务报告。与此同时，公司还向市场同步了其在近期取得的一系列重要业务进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109829073","title":"Aurinia Pharmaceuticals定于2026年2月26日公布2025财年第四季度及全年业绩并更新业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1109829073","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109829073?lang=zh_cn&edition=full","pubTime":"2026-02-19 19:02","pubTimestamp":1771498935,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals Inc (AUPH) 已宣布，将于2026年2月26日发布其截至2025年12月31日的第四季度及全年财务业绩报告。届时，公司管理层不仅会详细解读财报数据，还将同步介绍公司近期的关键业务动态与战略进展。此次发布将为投资者和市场观察人士提供一个全面了解公司财务状况与运营成效的重要窗口。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163649301","title":"Aurinia Pharmaceuticals 2024年第四季度GAAP每股收益$0.01超出$(0.02)的预期，销售额$59.87M低于$59.94M的预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1163649301","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163649301?lang=zh_cn&edition=full","pubTime":"2025-02-27 19:05","pubTimestamp":1740654320,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals  报告称季度每股收益为$0.01，超过了分析师一致预期的$，超出150%。公司报告的季度销售额为$59.87百万，低于分析师一致预期的$59.94百万，差距为0.13%。与去年同期$45.09百万的销售额相比，这增加了32.76%。以上内容来自Benzinga Earnings专栏，原文如下：Aurinia Pharmaceuticals  reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $ by 150 percent. This is a 105.26 percent increase over losses of $ per share from the same period last year.  The company reported quarterly sales of $59.87 million which missed the analyst consensus estimate o","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Aurinia Pharmaceuticals 2024年第四季度GAAP每股收益$0.01超出$(0.02)的预期，销售额$59.87M低于$59.94M的预期","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2490115780","title":"Aurinia Pharmaceuticals Inc盘中异动 大幅拉升5.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490115780","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490115780?lang=zh_cn&edition=full","pubTime":"2024-12-10 22:32","pubTimestamp":1733841172,"startTime":"0","endTime":"0","summary":"北京时间2024年12月10日22时32分，Aurinia Pharmaceuticals Inc股票出现波动，股价大幅上涨5.59%。截至发稿，该股报9.64美元/股，成交量19.1063万股，换手率0.13%，振幅1.53%。Aurinia Pharmaceuticals Inc股票所在的生物技术行业中，整体涨幅为0.01%。其相关个股中，Chimerix, Inc.、Uniqure N.V.、Klotho Neurosciences Inc C/Wts 21/06/2029 涨幅较大，Psyence Biomedical Ltd.、Processa Pharmaceuticals, Inc.、60 Degrees Pharmaceuticals, Inc.较为活跃，换手率分别为1717.09%、404.62%、88.15%，振幅较大的相关个股有Reviva Pharmaceuticals Holdings Inc C/Wts 25/12/2025、Psyence Biomedical Ltd.、Chimerix, Inc.，振幅分别为24.58%、21.74%、17.33%。Aurinia Pharmaceuticals Inc公司简介：Aurinia Pharmaceuticals Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210223253984b0be2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210223253984b0be2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2484924548","title":"Aurinia Pharmaceuticals Inc2024财年第三财季实现净利润14.35百万美元，同比增加206.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484924548","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484924548?lang=zh_cn&edition=full","pubTime":"2024-11-17 00:02","pubTimestamp":1731772946,"startTime":"0","endTime":"0","summary":"11月17日，Aurinia Pharmaceuticals Inc公布财报，公告显示公司2024财年第三财季净利润为14.35百万美元，同比增加206.69%；其中营业收入为67.77百万美元，同比增加24.30%，每股基本收益为0.10美元。机构评级：截至2024年11月17日，当前有7家机构对Aurinia Pharmaceuticals Inc目标价做出预测，其中目标均价为10.84美元，其中最低目标价为8.00美元，最高目标价为13.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000320a23e064a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000320a23e064a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154738439","title":"异动解读 | Aurinia Pharmaceuticals大幅裁员重组 盘中股价大涨7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1154738439","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154738439?lang=zh_cn&edition=full","pubTime":"2024-11-07 22:49","pubTimestamp":1730990947,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals Inc今日盘中大涨7.06%,引发了市场的广泛关注。公司宣布将进行大规模重组,包括裁员约28%的全职员工,优化临床开发项目组合,以及外包部分非核心职能等措施。重组过程中,Aurinia将继续专注于其主打产品Lupkynis的市场推广工作,并寻求与潜在战略合作伙伴的合作,以加速实现公司的商业目标。投资者对这一重组计划反映了积极态度,公司股价盘中大涨反映了市场对其未来发展前景的充满信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AUPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2481186028","title":"Aurinia Pharmaceuticals Inc盘中异动 早盘股价大涨7.05%报8.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481186028","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481186028?lang=zh_cn&edition=full","pubTime":"2024-11-07 22:31","pubTimestamp":1730989875,"startTime":"0","endTime":"0","summary":"北京时间2024年11月07日22时31分，Aurinia Pharmaceuticals Inc股票出现波动，股价大幅拉升7.05%。截至发稿，该股报8.05美元/股，成交量10.3461万股，换手率0.07%，振幅0.00%。Aurinia Pharmaceuticals Inc股票所在的生物技术行业中，整体涨幅为0.06%。其相关个股中，Tevogen Bio Holdings Inc C/Wts 14/02/2029 、Ensysce Biosciences, Inc.、Mustang Bio, Inc.涨幅较大，Ensysce Biosciences, Inc.、Elevai Labs, Inc.、Cyclacel Pharmaceuticals, Inc.较为活跃，换手率分别为76.92%、54.48%、47.54%，振幅较大的相关个股有Tuhura Biosciences, Inc.、Immunic, Inc.、Fennec Pharmaceuticals Inc.，振幅分别为8.54%、5.93%、4.85%。Aurinia Pharmaceuticals Inc公司简介：Aurinia Pharmaceuticals Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241107223115a220ec2e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241107223115a220ec2e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AUPH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163681819","title":"异动解读 | Aurinia Pharmaceuticals公司宣布重组计划 盘前股价大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=1163681819","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163681819?lang=zh_cn&edition=full","pubTime":"2024-11-07 22:26","pubTimestamp":1730989593,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals Inc (股票代码:AUPH)今日盘前大涨6.65%,引发市场广泛关注。公司宣布将进行重组,包括裁员和优化运营,旨在降低运营成本、提高效率。\n\nAurinia表示,在当前经济环境下,为了确保公司长期可持续发展,必须采取一些艰难但关键的措施。此次重组计划预计可节省大约1.25亿美元的年度运营支出。\n\n重组的具体内容包括裁员约28%的全职员工,优化临床开发项目组合,外包部分非核心职能等。Aurinia还将继续专注于其主打产品Lupkynis的市场推广,并寻求战略性合作伙伴关系,以加速实现商业目标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AUPH"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.auriniapharma.com","stockEarnings":[{"period":"1week","weight":-0.0478},{"period":"1month","weight":-0.1255},{"period":"3month","weight":-0.0502},{"period":"6month","weight":0.0551},{"period":"1year","weight":0.7264},{"period":"ytd","weight":-0.0389}],"compareEarnings":[{"period":"1week","weight":-0.0098},{"period":"1month","weight":0.0041},{"period":"3month","weight":0.055},{"period":"6month","weight":0.0844},{"period":"1year","weight":0.1885},{"period":"ytd","weight":0.096}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Aurinia Pharmaceuticals Inc.是根据《商业公司法》组建的（加拿大阿尔伯塔省）。Aurinia制药是一家完全整合的生物制药公司，专注于提供治疗目标患者群体的疗法，这些患者群体受到自身免疫、肾脏和罕见病的影响，医疗需求未得到满足。2021年1月，Aurinia制药推出了首个获得FDA批准的口服药物LUPKYNIS（voclosporin），用于治疗活动性LN成人患者。LUPKYNIS是一种口服CNI免疫抑制剂，当与霉酚酸酯（MMF）（尽管MMF目前尚未被批准）和类固醇联合使用时，已被证明可以改善LN的近期和长期结果。通过抑制钙调神经磷酸酶，LUPKYNIS降低细胞因子活化，阻断白细胞介素IL-2表达和T细胞介导的免疫反应。LUPKYNIS还可能稳定足细胞，从而防止蛋白尿。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.071692},{"month":2,"riseRate":0.416667,"avgChangeRate":0.005745},{"month":3,"riseRate":0.5,"avgChangeRate":0.089864},{"month":4,"riseRate":0.666667,"avgChangeRate":-0.004824},{"month":5,"riseRate":0.5,"avgChangeRate":-0.007754},{"month":6,"riseRate":0.5,"avgChangeRate":-0.009565},{"month":7,"riseRate":0.583333,"avgChangeRate":0.030035},{"month":8,"riseRate":0.545455,"avgChangeRate":-0.014541},{"month":9,"riseRate":0.454545,"avgChangeRate":0.063835},{"month":10,"riseRate":0.583333,"avgChangeRate":0.048963},{"month":11,"riseRate":0.583333,"avgChangeRate":0.036405},{"month":12,"riseRate":0.416667,"avgChangeRate":0.092842}],"exchange":"NASDAQ","name":"Aurinia Pharmaceuticals Inc","nameEN":"Aurinia Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aurinia Pharmaceuticals Inc(AUPH)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Aurinia Pharmaceuticals Inc(AUPH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Aurinia Pharmaceuticals Inc,AUPH,Aurinia Pharmaceuticals Inc股票,Aurinia Pharmaceuticals Inc股票老虎,Aurinia Pharmaceuticals Inc股票老虎国际,Aurinia Pharmaceuticals Inc行情,Aurinia Pharmaceuticals Inc股票行情,Aurinia Pharmaceuticals Inc股价,Aurinia Pharmaceuticals Inc股市,Aurinia Pharmaceuticals Inc股票价格,Aurinia Pharmaceuticals Inc股票交易,Aurinia Pharmaceuticals Inc股票购买,Aurinia Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aurinia Pharmaceuticals Inc(AUPH)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Aurinia Pharmaceuticals Inc(AUPH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}